Loading filters...
50 results(scroll for more)
GeneralAdvanced/Metastatic (IV)2026
Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial.
Yan C et al. JAMA Oncol. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP).
Zaanan A et al. Eur J Cancer. 2026
Claudin 18.2+All Stages2026
Chemotherapy-induced cell cycle arrest is associated with increased claudin-18 isoform 2 expression and enhanced zolbetuximab-mediated cytotoxicity in gastric cancer.
Takiguchi C et al. J Gastroenterol. 2026
GeneralResectable (I-III)2026
Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection: A Multicenter Cohort Study.
Sumiyoshi S et al. Ann Surg Oncol. 2026
Claudin 18.2+Advanced/Metastatic (IV)2026
Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.
Yamaguchi K et al. Gastric Cancer. 2026
GeneralAdvanced/Metastatic (IV)2026
Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study.
Ma X et al. Int J Cancer. 2026
PD-L1 positiveAll Stages2026
Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.
Nie RC et al. J Clin Oncol. 2026
HER2-positiveAll Stages2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T et al. J Clin Oncol. 2026
HER2-positiveAll Stages2026
Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.
Li W et al. Gastric Cancer. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy.
Lee Y et al. Int J Cancer. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
Prognostic implications of tissue-based homologous recombination deficiency in metastatic gastric cancer treated with immune checkpoint inhibitor plus chemotherapy.
Kim C et al. Gastric Cancer. 2026
GeneralAll Stages2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.
Shitara K et al. ESMO Open. 2026
GeneralAdvanced/Metastatic (IV)2026
Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial.
Kawabata R et al. Gastric Cancer. 2026
GeneralResectable (I-III)2026
Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.
Jin P et al. Int J Cancer. 2026
GeneralAll Stages2026
Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704.
Kurokawa Y et al. Gastric Cancer. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.
Janjigian YY et al. Ann Oncol. 2026
GeneralAdvanced/Metastatic (IV)2026
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Kawamoto Y et al. Gastric Cancer. 2026
GeneralAll Stages2026
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.
Endo S et al. Gastric Cancer. 2026
GeneralResectable (I-III)2026
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402).
Tanaka R et al. Gastric Cancer. 2026
GeneralResectable (I-III)2026
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).
Endo S et al. Gastric Cancer. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.
Lee KW et al. Clin Cancer Res. 2026
GeneralAdvanced/Metastatic (IV)2026
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.
Hille J et al. Int J Cancer. 2026
GeneralResectable (I-III)2026
A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma.
Kumagai K et al. J Gastroenterol. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Shitara K et al. N Engl J Med. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Treatment outcomes of trastuzumab-based chemotherapy in patients with HER2-positive gastric cancer: A nationwide retrospective cohort study.
Kim TH et al. Oncologist. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer.
Lee CK et al. ESMO Open. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer.
Yoshino K et al. Gastric Cancer. 2026
HER2-positiveAll Stages2026
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.
Liu R et al. Ann Oncol. 2026
HER2-positiveAll Stages2026
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
Sheng T et al. Gut. 2026
GeneralResectable (I-III)2026
Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.
Mateos L et al. Br J Cancer. 2026
GeneralAll Stages2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study.
Dos Santos M et al. Eur J Cancer. 2026
FGFR2+Advanced/Metastatic (IV)2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies.
Maron SB et al. ESMO Open. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.
Casak SJ et al. Clin Cancer Res. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Nakayama I et al. J Clin Oncol. 2026
PD-L1 positiveAdvanced/Metastatic (IV)2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Shitara K et al. Nat Med. 2026
GeneralAdvanced/Metastatic (IV)2026
Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.
Bilsland AE et al. Br J Cancer. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.
Shah MA et al. J Clin Oncol. 2026
GeneralResectable (I-III)2026
Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.
Airoldi M et al. ESMO Open. 2026
HER2-positiveAll Stages2025
YAP as a therapeutic target to reverse trastuzumab resistance.
Nam AR et al. Gastric Cancer. 2025
GeneralAdvanced/Metastatic (IV)2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G).
Matsubara Y et al. Int J Cancer. 2025
MSI-H/dMMRAdvanced/Metastatic (IV)2025
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Komori A et al. Gastric Cancer. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma.
Wallam S et al. J Gastrointest Oncol. 2025
PD-L1 positiveAdvanced/Metastatic (IV)2025
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.
Lin D et al. Gastric Cancer. 2025
GeneralResectable (I-III)2025
Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study.
Toyota K et al. Gastric Cancer. 2025
GeneralAll Stages2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.
Zaanan A et al. Lancet Oncol. 2025
GeneralAll Stages2025
Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.
Sugiyama K et al. Gastric Cancer. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms.
Sugiyama Y et al. Gastric Cancer. 2025
HER2-positiveAdvanced/Metastatic (IV)2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K et al. N Engl J Med. 2025
Claudin 18.2+Advanced/Metastatic (IV)2025
Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer.
Saito A et al. J Gastrointest Oncol. 2025
Claudin 18.2+All Stages2025
Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer.
Rosanu NM et al. Eur J Cancer. 2025